GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » NonCurrent Deferred Liabilities

HURA (TuHURA Biosciences) NonCurrent Deferred Liabilities : $0.00 Mil (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

TuHURA Biosciences's non-current deferred liabilities for the quarter that ended in Mar. 2025 was $0.00 Mil.

TuHURA Biosciences NonCurrent Deferred Liabilities Historical Data

The historical data trend for TuHURA Biosciences's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences NonCurrent Deferred Liabilities Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
NonCurrent Deferred Liabilities
- - - -

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

TuHURA Biosciences NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


TuHURA Biosciences Business Description

Traded in Other Exchanges
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.